Send the following on WhatsApp
Continue to Chathttps://kalkinemedia.com/news/prnews/the-nda-for-new-indication-of-henlius-anti-pd-1-mab-serplulimab-in-combination-with-chemotherapy-for-the-first-line-treatment-of-non-squamous-nsclc-accepted-by-the-nmpa